NASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis $5.19 -0.31 (-5.64%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$5.24 +0.05 (+1.06%) As of 05/2/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verve Therapeutics Stock (NASDAQ:VERV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verve Therapeutics alerts:Sign Up Key Stats Today's Range$5.16▼$5.6850-Day Range$2.97▼$6.7152-Week Range$2.86▼$9.31Volume2.92 million shsAverage Volume1.79 million shsMarket Capitalization$462.65 millionP/E RatioN/ADividend YieldN/APrice Target$25.75Consensus RatingBuy Company OverviewVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More… Verve Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreVERV MarketRank™: Verve Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 685th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingVerve Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerve Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Verve Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Verve Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.05% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Verve Therapeutics has recently decreased by 0.42%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.05% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Verve Therapeutics has recently decreased by 0.42%, indicating that investor sentiment is improving. News and Social Media4.0 / 5News Sentiment1.21 News SentimentVerve Therapeutics has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Verve Therapeutics this week, compared to 6 articles on an average week.Search Interest19 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days.MarketBeat Follows6 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,427.00 in company stock.Percentage Held by Insiders19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verve Therapeutics' insider trading history. Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Stock News HeadlinesVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Sells $11,524.55 in StockApril 4, 2025 | insidertrades.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2 at 4:05 PM | globenewswire.comGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.May 4, 2025 | Golden Portfolio (Ad)1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall StreetApril 29, 2025 | fool.comWhy Verve Therapeutics Zoomed 40% Higher This WeekApril 18, 2025 | fool.comBiotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More NewsApril 17, 2025 | finance.yahoo.comJ.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)April 16, 2025 | markets.businessinsider.comVerve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drugApril 15, 2025 | msn.comSee More Headlines VERV Stock Analysis - Frequently Asked Questions How have VERV shares performed this year? Verve Therapeutics' stock was trading at $5.64 at the beginning of the year. Since then, VERV stock has decreased by 8.0% and is now trading at $5.19. View the best growth stocks for 2025 here. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) posted its earnings results on Thursday, February, 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The firm earned $13.08 million during the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 35.23% and a negative net margin of 807.65%. When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $201 million in an IPO on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO. Who are Verve Therapeutics' major shareholders? Verve Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.25%), Rhumbline Advisers (0.12%), Green Alpha Advisors LLC (0.06%) and GAMMA Investing LLC (0.04%). Insiders that own company stock include Krishna Yeshwant, Fmr Llc, Andrew D Ashe, Sekar Kathiresan, Burt A Adelman, Joan Nickerson, Allison Dorval, Andrew Bellinger and 2017 Gp LLC Gv. View institutional ownership trends. How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verve Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings2/27/2025Today5/04/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VERV CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$25.75 High Stock Price Target$39.00 Low Stock Price Target$15.00 Potential Upside/Downside+396.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,070,000.00 Net Margins-807.65% Pretax Margin-806.39% Return on Equity-35.23% Return on Assets-27.65% Debt Debt-to-Equity RatioN/A Current Ratio13.05 Quick Ratio13.05 Sales & Book Value Annual Sales$32.33 million Price / Sales14.31 Cash FlowN/A Price / Cash FlowN/A Book Value$7.31 per share Price / Book0.71Miscellaneous Outstanding Shares89,143,000Free Float68,324,000Market Cap$462.65 million OptionableOptionable Beta1.86 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:VERV) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.